- Home
- REVB vs BJDX Comparison
REVB vs BJDX Comparison
Compare REVB & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- BJDX
- Stock Information
- Founded
- REVB 2020
- BJDX 2015
- Country
- REVB United States
- BJDX United States
- Employees
- REVB N/A
- BJDX N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- BJDX Medical Specialities
- Sector
- REVB Health Care
- BJDX Health Care
- Exchange
- REVB Nasdaq
- BJDX Nasdaq
- Market Cap
- REVB 2.3M
- BJDX 2.2M
- IPO Year
- REVB N/A
- BJDX 2021
- Fundamental
- Price
- REVB $2.67
- BJDX $3.70
- Analyst Decision
- REVB
- BJDX
- Analyst Count
- REVB 0
- BJDX 0
- Target Price
- REVB N/A
- BJDX N/A
- AVG Volume (30 Days)
- REVB 141.4K
- BJDX 35.9K
- Earning Date
- REVB 03-06-2025
- BJDX 05-14-2025
- Dividend Yield
- REVB N/A
- BJDX N/A
- EPS Growth
- REVB N/A
- BJDX N/A
- EPS
- REVB N/A
- BJDX N/A
- Revenue
- REVB N/A
- BJDX N/A
- Revenue This Year
- REVB N/A
- BJDX N/A
- Revenue Next Year
- REVB N/A
- BJDX N/A
- P/E Ratio
- REVB N/A
- BJDX N/A
- Revenue Growth
- REVB N/A
- BJDX N/A
- 52 Week Low
- REVB $2.36
- BJDX $3.03
- 52 Week High
- REVB $60.80
- BJDX $316.80
- Technical
- Relative Strength Index (RSI)
- REVB 32.04
- BJDX 45.28
- Support Level
- REVB $2.51
- BJDX $3.52
- Resistance Level
- REVB $2.92
- BJDX $4.02
- Average True Range (ATR)
- REVB 0.27
- BJDX 0.32
- MACD
- REVB 0.03
- BJDX -0.05
- Stochastic Oscillator
- REVB 28.44
- BJDX 14.06
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.